Status:
COMPLETED
A Study of LY900014 (Lyumjev) Versus Insulin Lispro (Humalog) in Participants With Type 1 Diabetes
Lead Sponsor:
Eli Lilly and Company
Conditions:
Diabetes Mellitus, Type 1
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
This study will be conducted in participants with type 1 diabetes mellitus on continuous subcutaneous insulin infusion (CSII) or pump therapy to evaluate the effect of LY900014 (Lyumjev) on blood suga...
Eligibility Criteria
Inclusion
- Male or female participants with type 1 diabetes
- Body mass index (BMI) between 18.5 and 29.0 kilograms per square meter (kg/m²), inclusive
- Hemoglobin A1c (HbA1c) less than or equal to 8.5 percent (%)
- Using CSII and stable insulin regimen for at least 6 months prior to inclusion into the trial
- Able to undergo at least 1 hour of moderate-intensity exercise
Exclusion
- Are currently participating or recently participated in a clinical trial or any other type of medical research judged to be incompatible with this study
- Have a blood loss of more than 500 milliliters (mL) within the last month
- Have known allergies to insulin lispro, related compounds or any components of the study drug formulation
- Have previously participated or withdrawn from this study
- Have or used to have health problems or medical test results that, in the opinion of the doctor, could make it unsafe to participate, or could interfere with understanding the results of the study
- Participants who have an abnormal blood pressure and/or pulse rate
- Participants with clinically significant cardiac or pulmonary disease
Key Trial Info
Start Date :
February 14 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 7 2023
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT05262387
Start Date
February 14 2022
End Date
March 7 2023
Last Update
September 3 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
LMC Clinical Research Inc. (Bayview)
Toronto, Ontario, Canada, M4G 3E8